COMMUNIQUÉS West-GlobeNewswire

PAT : Résultats semestriels 2024 non consolidés

30/10/2024 - 18:51

Vandœuvre-lès-Nancy, le 30 octobre 2024 - 18 : 00 (CET) Communiqué de presse Pour diffusion immédiate Résultats semestriels 2024 de PAT non consolidés Résultats au 30 juin 2024 bénéficiaires Chiffre d’affaires PAT : 1, [...]

Inventiva annonce la recommandation positive du cinquième DMC de l’étude clinique NATiV3 Phase 3 avec lanifibranor dans la MASH

30/10/2024 - 21:00

Le Data Monitoring Committee recommande sur la base d’une revue planifiée des données de sécurité que l’étude clinique de Phase III continue sans modification du protocole actuel. L’évaluation était basée sur l’examen [...]

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

30/10/2024 - 21:00

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review [...]

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

30/10/2024 - 21:00

Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to increased insulin [...]

MIMEDX Announces Third Quarter 2024 Operating and Financial Results

30/10/2024 - 21:01

Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05 , Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% [...]

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

30/10/2024 - 21:01

Achieved $20.1 million in OJEMDA TM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, [...]

Standard BioTools Reports Third Quarter 2024 Financial Results

30/10/2024 - 21:01

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024. [...]

HealthEquity Announces Third Quarter Earnings Release Date

30/10/2024 - 21:01

DRAPER, Utah, Oct. 30, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its [...]

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

30/10/2024 - 21:01

We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy. We are committed to addressing the high unmet needs of patients through a growing cell therapy and [...]

Amwell Announces Results for Third Quarter 2024

30/10/2024 - 21:05

BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter [...]

Merit Medical Reports Third Quarter 2024 Results and Raises Full-Year Guidance

30/10/2024 - 21:05

Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8% Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectively GAAP operating margin of 11.0%, compared to [...]

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

30/10/2024 - 21:05

-- Strong Cash Position of $306 Million; 9 th Consecutive Quarter of Positive or Neutral Cash Balance -- -- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partnerships and Early [...]

Cytek Biosciences to Participate in Upcoming Investor Conferences

30/10/2024 - 21:05

FREMONT, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

30/10/2024 - 21:05

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), Aligos a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class [...]

Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024

30/10/2024 - 21:05

AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the [...]

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

30/10/2024 - 21:05

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

30/10/2024 - 21:05

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]

Teladoc Health Reports Third Quarter 2024 Results

30/10/2024 - 21:05

PURCHASE, NY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended September 30, 2024 (“Third [...]

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

30/10/2024 - 21:15

First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ability to deliver more SN-38 to tumors compared with either irinotecan or [...]